REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab (MK-3475) in Untreated Extensive Small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2016
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms REACTION
- 11 Oct 2016 Planned End Date changed from 1 Sep 2019 to 1 Jun 2020.
- 11 Oct 2016 Planned primary completion date changed from 1 Jan 2019 to 1 Oct 2019.
- 11 Oct 2016 Planned initiation date changed from 1 Mar 2016 to 1 Jan 2017.